2018
Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study
Jeffery MM, Hooten WM, Henk HJ, Bellolio MF, Hess EP, Meara E, Ross JS, Shah ND. Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study. The BMJ 2018, 362: k2833. PMID: 30068513, PMCID: PMC6066997, DOI: 10.1136/bmj.k2833.Peer-Reviewed Original ResearchConceptsMedicare Advantage beneficiariesAverage daily doseDisabled Medicare beneficiariesAged Medicare beneficiariesRetrospective cohort studyDaily doseOpioid useMedicare beneficiariesLong-term useCohort studyCommercial beneficiariesStudy periodUse prevalenceOpioid use prevalenceHigh rateMedicare Advantage populationTerm useAge 65 yearsOpioid use ratesAdministrative claims dataAverage daily dosesProportion of beneficiariesQuarterly prevalenceMorphine equivalentsOpioid prescriptions
2017
Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection
Jeffery MM, Shah ND, Karaca-Mandic P, Ross JS, Rank MA. Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection. The Journal Of Allergy And Clinical Immunology In Practice 2017, 6: 1568-1577.e4. PMID: 28958746, DOI: 10.1016/j.jaip.2017.07.034.Peer-Reviewed Original ResearchConceptsOmalizumab initiationAsthma controlICS-LABAPatient selectionLow adherenceBetter asthma controlCohort of nonusersSuboptimal patient selectionPoor asthma controlLow adherence ratesPatient-level characteristicsLarge US databaseMedicare Advantage beneficiariesAsthma biologicsExacerbation frequencyOmalizumab useIncident useComparison cohortICS/Medication adherenceAdherence ratesPrevalent usersAdministrative claimsAsthmaUtilization trends